Published in AIDS on July 17, 2010
Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D:A:D study. J Infect Dis (2013) 3.04
Future challenges for clinical care of an ageing population infected with HIV: a modelling study. Lancet Infect Dis (2015) 2.96
Association of tenofovir exposure with kidney disease risk in HIV infection. AIDS (2012) 2.65
Changes in glomerular kidney function among HIV-1-uninfected men and women receiving emtricitabine-tenofovir disoproxil fumarate preexposure prophylaxis: a randomized clinical trial. JAMA Intern Med (2015) 2.35
Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis (2014) 2.16
Rosuvastatin preserves renal function and lowers cystatin C in HIV-infected subjects on antiretroviral therapy: the SATURN-HIV trial. Clin Infect Dis (2014) 1.68
Baseline kidney function as predictor of mortality and kidney disease progression in HIV-positive patients. Am J Kidney Dis (2012) 1.62
Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study. PLoS One (2016) 1.38
Risk factors for chronic kidney disease in a large cohort of HIV-1 infected individuals initiating antiretroviral therapy in routine care. AIDS (2012) 1.38
Trends in reasons for hospitalization in a multisite United States cohort of persons living with HIV, 2001-2008. J Acquir Immune Defic Syndr (2012) 1.37
Metabolic effects of darunavir/ritonavir versus atazanavir/ritonavir in treatment-naive, HIV type 1-infected subjects over 48 weeks. AIDS Res Hum Retroviruses (2012) 1.35
Hepatitis B and C co-infection are independent predictors of progressive kidney disease in HIV-positive, antiretroviral-treated adults. PLoS One (2012) 1.16
Renal disease in HIV-infected individuals. Curr Opin HIV AIDS (2011) 1.15
Antiretroviral regimens sparing agents from the nucleoside(tide) reverse transcriptase inhibitor class: a review of the recent literature. AIDS Res Ther (2013) 1.08
Effect of baseline renal function on tenofovir-containing antiretroviral therapy outcomes in Zambia. Clin Infect Dis (2014) 1.07
Estimating kidney function in HIV-infected adults in Kenya: comparison to a direct measure of glomerular filtration rate by iohexol clearance. PLoS One (2013) 1.04
Comparisons of creatinine and cystatin C for detection of kidney disease and prediction of all-cause mortality in HIV-infected women. AIDS (2013) 1.01
Role of traditional risk factors and antiretroviral drugs in the incidence of chronic kidney disease, ANRS CO3 Aquitaine cohort, France, 2004-2012. PLoS One (2013) 0.98
Comorbid diabetes and the risk of progressive chronic kidney disease in HIV-infected adults: data from the Veterans Aging Cohort Study. J Acquir Immune Defic Syndr (2012) 0.98
Ritonavir-boosted darunavir is rarely associated with nephrolithiasis compared with ritonavir-boosted atazanavir in HIV-infected patients. PLoS One (2013) 0.98
Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study. PLoS Med (2015) 0.97
Incomplete reversibility of estimated glomerular filtration rate decline following tenofovir disoproxil fumarate exposure. J Infect Dis (2014) 0.96
Relative risk of renal disease among people living with HIV: a systematic review and meta-analysis. BMC Public Health (2012) 0.96
Prevalence and risk factors associated to chronic kidney disease in HIV-infected patients on HAART and undetectable viral load in Brazil. PLoS One (2011) 0.94
Tenofovir plasma concentrations according to companion drugs: a cross-sectional study of HIV-positive patients with normal renal function. Antimicrob Agents Chemother (2013) 0.93
Factors affecting glomerular filtration rate, as measured by iohexol disappearance, in men with or at risk for HIV infection. PLoS One (2014) 0.93
Full-length soluble urokinase plasminogen activator receptor down-modulates nephrin expression in podocytes. Sci Rep (2015) 0.93
N-terminal-proB-type natriuretic peptide predicts cardiovascular disease events in HIV-infected patients. AIDS (2011) 0.91
Prevalence of renal disease within an urban HIV-infected cohort in northern Italy. Clin Exp Nephrol (2013) 0.89
Impact of a tenofovir disoproxil fumarate plus ritonavir-boosted protease inhibitor-based regimen on renal function in HIV-infected individuals: a prospective, multicenter study. BMC Infect Dis (2013) 0.89
Tenofovir-induced nephrotoxicity: incidence, mechanism, risk factors, prognosis and proposed agents for prevention. Eur J Clin Pharmacol (2014) 0.88
Atazanavir nephrotoxicity. Clin Kidney J (2015) 0.88
The New Epidemiology of HIV-Related Kidney Disease. J AIDS Clin Res (2012) 0.86
Update on current management of chronic kidney disease in patients with HIV infection. Int J Nephrol Renovasc Dis (2016) 0.85
Changes in proteinuria and albuminuria with initiation of antiretroviral therapy: data from a randomized trial comparing tenofovir disoproxil fumarate/emtricitabine versus abacavir/lamivudine. J Acquir Immune Defic Syndr (2014) 0.84
Neither proteinuria nor albuminuria is associated with endothelial dysfunction in HIV-infected patients without diabetes or hypertension. J Infect Dis (2011) 0.84
Cystatin C-based renal function changes after antiretroviral initiation: a substudy of a randomized trial. Open Forum Infect Dis (2014) 0.83
Protease Inhibitors and Renal Function in Patients with HIV Infection: a Systematic Review. Infect Dis Ther (2015) 0.83
Abacavir/lamivudine versus tenofovir/emtricitabine in virologically suppressed patients switching from ritonavir-boosted protease inhibitors to raltegravir. AIDS Res Hum Retroviruses (2012) 0.81
Total protein, albumin and low-molecular-weight protein excretion in HIV-positive patients. BMC Nephrol (2012) 0.81
Accelerated Aging in HIV Patients. Rambam Maimonides Med J (2012) 0.81
Screening for decreased glomerular filtration rate and associated risk factors in a cohort of HIV-infected patients in a middle-income country. PLoS One (2014) 0.81
Elevations in Serum Creatinine With Tenofovir-Based HIV Pre-Exposure Prophylaxis: A Meta-Analysis of Randomized Placebo-Controlled Trials. J Acquir Immune Defic Syndr (2016) 0.80
Diabetes and Hypertension among Patients Receiving Antiretroviral Treatment Since 1998 in Senegal: Prevalence and Associated Factors. ISRN AIDS (2012) 0.80
Impaired Urine Dilution Capability in HIV Stable Patients. Int J Nephrol (2014) 0.80
A comparison of estimated glomerular filtration rates using Cockcroft-Gault and the Chronic Kidney Disease Epidemiology Collaboration estimating equations in HIV infection. HIV Med (2013) 0.80
Liver and renal safety of tenofovir disoproxil fumarate in combination with emtricitabine among African women in a pre-exposure prophylaxis trial. BMC Pharmacol Toxicol (2014) 0.79
A review of cardiovascular and renal function monitoring: a consideration of older adults with HIV. HIV AIDS (Auckl) (2013) 0.78
WHO antiretroviral therapy guidelines 2010 and impact of tenofovir on chronic kidney disease in Vietnamese HIV-infected patients. PLoS One (2013) 0.78
Proteinuria in paediatric patients with human immunodeficiency virus infection. World J Clin Cases (2013) 0.78
Drug Transporter Genetic Variants Are Not Associated with TDF-Related Renal Dysfunction in Patients with HIV-1 Infection: A Pharmacogenetic Study. PLoS One (2015) 0.78
Expert opinion on pharmacotherapy of kidney disease in HIV-infected patients. Expert Opin Pharmacother (2011) 0.77
Development of a definition for Rapid Progression (RP) of renal function in HIV-positive persons: the D:A:D study. BMC Nephrol (2014) 0.77
Frequent injection cocaine use increases the risk of renal impairment among hepatitis C and HIV coinfected patients. AIDS (2016) 0.76
Urine liver-type fatty acid-binding protein and kidney injury molecule-1 in HIV-infected patients receiving combined antiretroviral treatment based on tenofovir. AIDS Res Hum Retroviruses (2013) 0.76
Albuminuria Is Associated with Traditional Cardiovascular Risk Factors and Viral Load in HIV-Infected Patients in Rural South Africa. PLoS One (2015) 0.75
Effect of Tenofovir Disoproxil Fumarate on Incidence of Chronic Kidney Disease and Rate of Estimated Glomerular Filtration Rate Decrement in HIV-1-Infected Treatment-Naïve Asian Patients: Results from 12-Year Observational Cohort. AIDS Patient Care STDS (2017) 0.75
Relationships between Serum Levels of Atazanavir and Renal Toxicity or Lithiasis. AIDS Res Treat (2015) 0.75
Improved kidney function in patients who switch their protease inhibitor from atazanavir or lopinavir to darunavir. AIDS (2017) 0.75
Effects of a switch from tenofovir- to abacavir-based antiretroviral therapy, with or without atazanavir, on renal function. J Int AIDS Soc (2016) 0.75
An Increase in Serum Creatinine after Initiation of Fenofibrate in an HIV-Infected Individual: A Case Report and Review of the Literature. J Int Assoc Physicians AIDS Care (Chic) (2011) 0.75
Tenofovir is associated with increased tubular proteinuria and asymptomatic renal tubular dysfunction in Ghana. BMC Nephrol (2015) 0.75
Relationships between renal parameters and serum and urine markers of inflammation in those with and without HIV infection. AIDS Res Hum Retroviruses (2015) 0.75
Impact of comorbidities and drug therapy on development of renal impairment in a predominantly African American and Hispanic HIV clinic population. HIV AIDS (Auckl) (2011) 0.75
Antiretroviral-treated HIV-infected women have similar long-term kidney function trajectories as HIV-uninfected women. AIDS Res Hum Retroviruses (2013) 0.75
Antiretroviral therapy: when to start. Infect Dis Clin North Am (2014) 0.75
Acute Kidney Injury in HIV Infection. J Trop Dis (2013) 0.75
Changes in Urinary Biomarkers over 10 Years is Associated with Viral Suppression in a Prospective Cohort of Women Living with HIV. J Acquir Immune Defic Syndr (2016) 0.75
Estimation of renal function by CKD-EPI versus MDRD in a cohort of HIV-infected patients: a cross-sectional analysis. BMC Nephrol (2017) 0.75
HIV and kidney diseases: 35 years of history and consequences. Clin Kidney J (2016) 0.75
Long-Term Durability of Tenofovir-Based Antiretroviral Therapy in Relation to the Co-Administration of Other Drug Classes in Routine Clinical Practice. PLoS One (2016) 0.75
Antiretroviral therapy-induced changes in plasma lipids and the risk of kidney dysfunction in HIV-infected men. AIDS Res Hum Retroviruses (2013) 0.75
Estimated Glomerular Filtration Rate Trajectories in HIV-Infected Subjects Treated With Different Ritonavir-Boosted Protease Inhibitors and Tenofovir Disoproxil Fumarate or Abacavir. Medicine (Baltimore) (2016) 0.75
Risk of Chronic Kidney Disease among Patients Developing Mild Renal Impairment during Tenofovir-Containing Antiretroviral Treatment. PLoS One (2016) 0.75
Impact of protease inhibitors on the evolution of urinary markers: Subanalyses from an observational cross-sectional study. Medicine (Baltimore) (2016) 0.75
Proteinuria is common among HIV patients: what are we missing? Clinics (Sao Paulo) (2015) 0.75
Hepatitis C co-infection is associated with an increased risk of incident chronic kidney disease in HIV-infected patients initiating combination antiretroviral therapy. BMC Infect Dis (2017) 0.75
Lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients. BMC Infect Dis (2017) 0.75
Human Immunodeficiency Virus as a Chronic Disease: Evaluation and Management of Nonacquired Immune Deficiency Syndrome-Defining Conditions. Open Forum Infect Dis (2016) 0.75
The 6R's of drug induced nephrotoxicity. BMC Nephrol (2017) 0.75
Changes in estimated glomerular filtration rate over time in South African HIV-1-infected patients receiving tenofovir: a retrospective cohort study. J Int AIDS Soc (2017) 0.75
Prevalence, evolution, and related risk factors of kidney disease among Spanish HIV-infected individuals. Medicine (Baltimore) (2017) 0.75
Increased non-HDL-C level linked with a rapid rate of renal function decline in HIV-infected patients. Clin Exp Nephrol (2016) 0.75
Renal abnormalities in a cohort of HIV-infected children and adolescents. Pediatr Nephrol (2015) 0.75
Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet (2002) 16.56
A whole-genome association study of major determinants for host control of HIV-1. Science (2007) 15.19
Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. N Engl J Med (2015) 15.06
Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet (2009) 14.01
Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med (2008) 13.72
Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med (2007) 12.93
Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med (2003) 12.23
Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA (2008) 11.72
Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA (2010) 9.26
Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med (2006) 9.21
Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA (2012) 8.94
Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet (2008) 8.73
Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. J Infect Dis (2008) 6.73
Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. Lancet (2005) 6.60
Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect Dis (2008) 5.94
Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study. AIDS (2003) 5.61
Procalcitonin-guided interventions against infections to increase early appropriate antibiotics and improve survival in the intensive care unit: a randomized trial. Crit Care Med (2011) 5.28
Incidence of Tuberculosis among HIV-infected patients receiving highly active antiretroviral therapy in Europe and North America. Clin Infect Dis (2005) 5.20
HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis. Lancet (2006) 5.00
Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS (2005) 4.40
Morbidity and aging in HIV-infected persons: the Swiss HIV cohort study. Clin Infect Dis (2011) 4.31
Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. AIDS (2007) 4.31
HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity. BMJ (2009) 4.19
Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. Diabetes Care (2008) 4.10
HIV treatment as prevention: systematic comparison of mathematical models of the potential impact of antiretroviral therapy on HIV incidence in South Africa. PLoS Med (2012) 4.08
Common genetic variation and the control of HIV-1 in humans. PLoS Genet (2009) 3.68
Inflammation, coagulation and cardiovascular disease in HIV-infected individuals. PLoS One (2012) 3.68
Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. Lancet (2004) 3.59
Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis (2011) 3.59
Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy. Clin Infect Dis (2005) 3.57
Public-health and individual approaches to antiretroviral therapy: township South Africa and Switzerland compared. PLoS Med (2008) 3.56
Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study. AIDS (2010) 3.47
CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study. Arch Intern Med (2003) 3.41
The role of HIV in serious diseases other than AIDS. AIDS (2008) 3.39
Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ Cell counts and HIV RNA levels during follow-up. J Infect Dis (2008) 3.35
Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis (2010) 3.30
CD4 cell counts of 800 cells/mm3 or greater after 7 years of highly active antiretroviral therapy are feasible in most patients starting with 350 cells/mm3 or greater. J Acquir Immune Defic Syndr (2007) 3.18
Projected life expectancy of people with HIV according to timing of diagnosis. AIDS (2012) 3.09
Changing incidence of central nervous system diseases in the EuroSIDA cohort. Ann Neurol (2004) 3.06
Cohort profile: the Swiss HIV Cohort study. Int J Epidemiol (2009) 3.05
Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D:A:D study. J Infect Dis (2013) 3.04
Life expectancy of recently diagnosed asymptomatic HIV-infected patients approaches that of uninfected individuals. AIDS (2010) 2.98
Improved virological outcome in White patients infected with HIV-1 non-B subtypes compared to subtype B. Clin Infect Dis (2011) 2.98
HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load. JAMA (2001) 2.95
Interruption of antiretroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection: exploratory analyses from the SMART trial. Antivir Ther (2008) 2.93
A clinically prognostic scoring system for patients receiving highly active antiretroviral therapy: results from the EuroSIDA study. J Infect Dis (2002) 2.87
All-cause mortality in treated HIV-infected adults with CD4 ≥500/mm3 compared with the general population: evidence from a large European observational cohort collaboration. Int J Epidemiol (2011) 2.80
Immunodeficiency at the start of combination antiretroviral therapy in low-, middle-, and high-income countries. J Acquir Immune Defic Syndr (2014) 2.79
Association of noncirrhotic portal hypertension in HIV-infected persons and antiretroviral therapy with didanosine: a nested case-control study. Clin Infect Dis (2009) 2.78
Mortality and progression to AIDS after starting highly active antiretroviral therapy. AIDS (2003) 2.78
Late presenters in the era of highly active antiretroviral therapy: uptake of and responses to antiretroviral therapy. AIDS (2004) 2.76
Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J Infect Dis (2005) 2.73